Anti-estrogen resistance in human breast tumors Is driven by JAG1-NOTCH4-dependent cancer stem cell activity.
AuthorsSimões, Bruno M
O'Brien, Ciara S
Alférez, Denis G
Howell, Sacha J
Clarke, Robert B
AffiliationBreast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Wilmslow Road, Manchester M20 4BX
MetadataShow full item record
AbstractBreast cancers (BCs) typically express estrogen receptors (ERs) but frequently exhibit de novo or acquired resistance to hormonal therapies. Here, we show that short-term treatment with the anti-estrogens tamoxifen or fulvestrant decrease cell proliferation but increase BC stem cell (BCSC) activity through JAG1-NOTCH4 receptor activation both in patient-derived samples and xenograft (PDX) tumors. In support of this mechanism, we demonstrate that high ALDH1 predicts resistance in women treated with tamoxifen and that a NOTCH4/HES/HEY gene signature predicts for a poor response/prognosis in 2 ER+ patient cohorts. Targeting of NOTCH4 reverses the increase in Notch and BCSC activity induced by anti-estrogens. Importantly, in PDX tumors with acquired tamoxifen resistance, NOTCH4 inhibition reduced BCSC activity. Thus, we establish that BCSC and NOTCH4 activities predict both de novo and acquired tamoxifen resistance and that combining endocrine therapy with targeting JAG1-NOTCH4 overcomes resistance in human breast cancers.
CitationAnti-estrogen resistance in human breast tumors Is driven by JAG1-NOTCH4-dependent cancer stem cell activity. 2015, 12 (12):1968-77 Cell Rep
- Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
- Authors: Lombardo Y, Faronato M, Filipovic A, Vircillo V, Magnani L, Coombes RC
- Issue date: 2014 Jun 11
- A study on Notch signaling in human breast cancer.
- Authors: Zang S, Ji Ch, Qu X, Dong X, Ma D, Ye J, Ma R, Dai J, Guo D
- Issue date: 2007
- Reactive astrocytes promote the metastatic growth of breast cancer stem-like cells by activating Notch signalling in brain.
- Authors: Xing F, Kobayashi A, Okuda H, Watabe M, Pai SK, Pandey PR, Hirota S, Wilber A, Mo YY, Moore BE, Liu W, Fukuda K, Iiizumi M, Sharma S, Liu Y, Wu K, Peralta E, Watabe K
- Issue date: 2013 Mar
- FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
- Authors: McClements L, Annett S, Yakkundi A, O'Rourke M, Valentine A, Moustafa N, Alqudah A, Simões BM, Furlong F, Short A, McIntosh SA, McCarthy HO, Clarke RB, Robson T
- Issue date: 2019 Apr 11
- PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.
- Authors: Santiago-Gómez A, Kedward T, Simões BM, Dragoni I, NicAmhlaoibh R, Trivier E, Sabin V, Gee JM, Sims AH, Howell SJ, Clarke RB
- Issue date: 2019 Aug 28